» Articles » PMID: 35562420

The Effect of Calcium and Vitamin D Supplements on Blood Pressure in Postmenopausal Women: Myth or Reality?

Overview
Journal Hypertens Res
Date 2022 May 13
PMID 35562420
Authors
Affiliations
Soon will be listed here.
Abstract

Hypertension is a highly prevalent disease with serious cardiovascular and renal complications. Many studies have demonstrated a weak correlation between the consumption of calcium (or calcium plus vitamin D) and blood pressure, suggesting that calcium supplements might reduce blood pressure. However, the results to date remain controversial. In this study, we assessed the effect of calcium and vitamin D supplementation on the blood pressure of postmenopausal women with hypertension as a population group in which the use of calcium supplements is prevalent. This triple-blind randomized clinical trial enrolled 98 women of postmenopausal age with hypertension in 2019. The study period was 8 weeks with close follow-up. We used 24-h ambulatory blood pressure monitoring to record the initial and final blood pressure in all participants. The changes in both the mean systolic (p = 0.047) and diastolic blood pressure (p = 0.015) were suggestive of an increase in blood pressure after consuming calcium and vitamin D supplements. Among patients who had been using calcium channel blockers, calcium and vitamin D supplementation caused a notable increase compared to baseline systolic (p = 0.019) and diastolic blood pressures (p = 0.001). The present results differ from those of previous studies. This suggests that calcium supplementation for postmenopausal women with hypertension requires the close observation of blood pressure to prevent any further increase, especially in women who are being treated with calcium channel blockers (clinicaltrial.gov registration: NCT04618952).

Citing Articles

Vitamin D and hypertension: Is there any significant relation?.

Vakkalagadda N, Narayana S, Sree G, Bethineedi L, Kutikuppala L, Medarametla G Chronic Dis Transl Med. 2024; 10(2):156-158.

PMID: 38872764 PMC: 11166674. DOI: 10.1002/cdt3.83.


2023 update and perspectives.

Mogi M, Tanaka A, Node K, Tomitani N, Hoshide S, Narita K Hypertens Res. 2023; 47(1):6-32.

PMID: 37710033 DOI: 10.1038/s41440-023-01398-5.

References
1.
Dorans K, Mills K, Liu Y, He J . Trends in Prevalence and Control of Hypertension According to the 2017 American College of Cardiology/American Heart Association (ACC/AHA) Guideline. J Am Heart Assoc. 2018; 7(11). PMC: 6015372. DOI: 10.1161/JAHA.118.008888. View

2.
Lorell B, Carabello B . Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation. 2000; 102(4):470-9. DOI: 10.1161/01.cir.102.4.470. View

3.
Susic D, Frohlich E . Hypertensive Cardiovascular and Renal Disease and Target Organ Damage: Lessons from Animal Models. Cardiorenal Med. 2012; 1(3):139-146. PMC: 3130985. DOI: 10.1159/000329334. View

4.
Nguyen Q, Dominguez J, Nguyen L, Gullapalli N . Hypertension management: an update. Am Health Drug Benefits. 2014; 3(1):47-56. PMC: 4106550. View

5.
Appel L, Brands M, Daniels S, Karanja N, Elmer P, Sacks F . Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension. 2006; 47(2):296-308. DOI: 10.1161/01.HYP.0000202568.01167.B6. View